永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06978 永泰生物-B

已收盘 05-19 15:56:34

0.820

-0.010

-1.20%

最高0.840	最低0.800	成交量54.10万
今开0.830	昨收0.830	日振幅4.82%
总市值5.07亿	流通市值5.07亿	总股本6.18亿
成交额44.34万	换手率0.09%	流通股本6.18亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06978","market":"HK","secType":"STK","nameCN":"永泰生物-B","latestPrice":0.82,"timestamp":1779177394197,"preClose":0.83,"halted":0,"volume":541000,"delay":0,"changeRate":-0.012048192771084348,"floatShares":618000000,"shares":618000000,"eps":-0.4831176032896024,"marketStatus":"已收盘","change":-0.01,"latestTime":"05-19 15:56:34","open":0.83,"high":0.84,"low":0.8,"amount":443440,"amplitude":0.048193,"askPrice":0.85,"askSize":10000,"bidPrice":0.82,"bidSize":40000,"shortable":0,"etf":0,"ttmEps":-0.4762159232426081,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779240600000},"marketStatusCode":5,"adr":0,"listingDate":1594310400000,"exchange":"SEHK","adjPreClose":0.83,"openAndCloseTimeList":[[1779154200000,1779163200000],[1779166800000,1779177600000]],"volumeRatio":0.467303,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06978","defaultTab":"news","newsList":[{"id":"2636030884","title":"【券商聚焦】招银国际：AI有望改变创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2636030884","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636030884?lang=zh_cn&edition=full","pubTime":"2026-05-19 13:13","pubTimestamp":1779167581,"startTime":"0","endTime":"0","summary":"当前，监管框架持续完善，传统药企与AI原生公司加速合作，AI制药正处于从研发提效工具迈向创新药研发范式重构的转折期。AI重构药物研发全链条，早期效率红利已率先显现。传统创新药研发长期受困于高成本、长周期和低成功率，AI技术正在改变靶点发现、分子筛选与优化等关键环节的研发范式。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWU1MjY1NDI2Mjg5NDIzOQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981743","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348827113.USD","LU0315179316.USD","LU1226288170.HKD","02142","LU0348767384.USD","LU1719994722.HKD","01177","LU0140636845.USD","01801","CHAT","02616","LU1960683339.HKD","09995","LU1152091168.USD","IE00B031HY20.USD","BK1588","LU0067412154.USD","LU0456827905.SGD","LU0072913022.USD","LU0634319403.HKD","LU0456846285.SGD","LU0561508036.HKD","ARTY","LU2097828631.EUR","AIPO","09926","06185","BK1589","LU0856984785.SGD","LU1993786604.SGD","09688","06160","LU1303224171.USD","BK1161","LU0572944931.SGD","06978","159992","BK1583","01877","LU0417516738.SGD","LU1880383366.USD","02269","LU1226287792.SGD","LU1152091754.HKD","AGIX","SG9999002562.SGD","LU0516422952.EUR","IE00BPRC5H50.USD","LU0326950275.SGD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700080","title":"广药接手达安基因；阿斯利康高血压创新药获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700080","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636700080?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:01","pubTimestamp":1779148914,"startTime":"0","endTime":"0","summary":"政策动向2026年医保目录调整新增预申报允许商保创新药申报医保目录国家医保局介绍2026年国家医保药品目录及商业健康保险创新药品目录调整工作安排，包括首次允许纳入2025年商保创新药目录的药品申报国家医保目录，新增“预申报”环节等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741160824.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741160824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0046","LU1829250122.USD","BK0028","BK0168","LU0889565916.HKD","LU0058720904.USD","BK1161","06978","BK4588","BK4585","LU2237443978.SGD","BK1574","LABU","159992","002030","LU2237443465.HKD","LU2237443549.SGD","AZNH","LU2237443895.HKD","BK0188","LU2237443382.USD","LU2417539215.USD","BK4568","BK0159","LU0320765992.SGD","BK0042","LU2456880835.USD","LU0289739699.SGD","LU2236285917.USD","BK4007","LU0109394709.USD","BK0122","BK0239","LU2462157665.USD","LU2237443622.USD","AZN","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636026816","title":"恒瑞医药：公司已有瑞拉芙普α、瑞康曲妥珠单抗、阿得贝利单抗等多款生物制品类创新药获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2636026816","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636026816?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:48","pubTimestamp":1779094139,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：你好，贵司2025年新成立的生物制药事业部，请问在生物制药方面有什么新的进展？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740505938.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740505938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2543165471.USD","LU1781817850.SGD","BK0183","BK0196","LU1580142542.USD","LU1328615791.USD","BK0188","LU0405327494.USD","BK1191","LU1146622755.USD","06978","LU2097828714.EUR","LU1023057109.AUD","LU0359202008.SGD","BK0028","LU2328871848.SGD","LU2495084118.USD","LU2580892862.HKD","LU0359201885.HKD","01276","LU2097828805.USD","LU1064130708.USD","BK1574","BK0060","LU1997245177.USD","LU1820825898.SGD","LU2488822045.USD","LU2097828631.EUR","IPOS","LU2097828474.EUR","LU1997244956.HKD","LU2289578879.USD","BK1161","LU1255011170.USD","LU2148510915.USD","159992","LU1655091616.SGD","LU2580892789.USD","LU2097828557.USD","BK0239","LU1969619763.USD","LU1997245094.SGD","LU0405327148.USD","BK0012","LU1064131003.USD","600276","LU0359201612.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636428420","title":"阿里健康(00241)下跌3.54% 机构指利润或因投资于创新药、医疗AI而下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2636428420","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636428420?lang=zh_cn&edition=full","pubTime":"2026-05-18 14:00","pubTimestamp":1779084049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 阿里健康 跌超3%，截止发稿，最新报4.10港元，下跌3.54%，成交额4.87亿港元。消息面上，里昂研究认为，阿里健康26财年下半年收入略低于预期，但利润大致符合预期。该行认为，创新药继续是阿里健康的战略增长动力，但利润或会因持续投资于创新药和医疗人工智能而下跌。里昂下调阿里健康2027至2028财年经调整净利润预测23%，目标价相应由5.3港元下调至4.7港元，对应潜在升幅11%。","market":"us","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981614","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159992","BK1615","HK0000165453.HKD","BK1571","BK1189","BK1142","00241","150261","BK1247","BK1591","BK1501","BK1584","BK1515","BK1610","BK1589","BK1574","BK1161","BK1502","BK1617","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636046305","title":"港股异动 | 创新药概念股全线下挫 全球债市抛售潮初现 高利率或冲击行业估值及融资端","url":"https://stock-news.laohu8.com/highlight/detail?id=2636046305","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636046305?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:38","pubTimestamp":1779075485,"startTime":"0","endTime":"0","summary":"消息面上，霍尔木兹海峡持续封锁，正推动油价攀升至每桶105美元以上。全球债券市场抛售潮征兆已现。美国10年期国债收益率升至4.5%以上，日本30年期国债收益率首次突破4%，英国长期国债收益率则升至28年来的最高水平，引发市场对于未来全球金融环境趋紧的担忧。其中，4 月全球、美国、国内创新药投融资均呈现强劲复苏的态势。但也有分析人士指出，若全球利率环境进入更高水平且持续，将冲击创新药行业估值及融资端。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06978","BK1587","VXUS","09141","02171","03141","09939","BK1585","BK4588","09966","159992","02137","BK1161","BK1515","BK4585","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636045071","title":"从BD热潮到全球化稳健竞速：中国创新药“价值洼地”待破局","url":"https://stock-news.laohu8.com/highlight/detail?id=2636045071","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636045071?lang=zh_cn&edition=full","pubTime":"2026-05-18 11:14","pubTimestamp":1779074040,"startTime":"0","endTime":"0","summary":"当下，全球生物医药行业正经历一场深刻的周期重构。在资本寒冬余波未尽与监管政策动态调整的交织影响下，中国创新药企正从过去“跟随式”创新的角色，迈向全球创新“发源地”的关键转型期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605183740183766.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605183740183766.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","06978","159992","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636048086","title":"创新药概念走软 药明合联(02268)领跌5.57% 机构成仍看好以创新为主医药科技主线","url":"https://stock-news.laohu8.com/highlight/detail?id=2636048086","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636048086?lang=zh_cn&edition=full","pubTime":"2026-05-18 10:09","pubTimestamp":1779070152,"startTime":"0","endTime":"0","summary":"金吾财讯 | 创新药概念整体走软，截至发稿，药明合联 跌5.57%，亚盛医药-B跌5.50%，四环医药跌4.55%，康方生物跌4.49%，歌礼制药-B跌4.36%，同源康医药-B跌4.31%，康诺亚-B跌4.24%，荣昌生物跌4.14%。展望2026年，该机构继续看好以创新为主的医药科技主线，重点关注创新药、脑机接口、AI医疗、手术机器人等，同时建议布局2026年行业有望迎来反转的老龄化及院外消费，关注估值较低的麻药、血制品、中药等。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/ZDlhMzNiODA0MWQ5OWM0NDQ5YzUxMTZmZWRlMTczNjQ3MzM4NzkwNQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981521","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","LU1794554557.SGD","BK1600","06978","BK1587","LU0348735423.USD","09926","LU0417516902.SGD","LU2778985437.USD","BK1583","06855","SG9999014674.SGD","BK1593","LU2488822045.USD","09995","IE00B543WZ88.USD","LU0540923850.HKD","02410","LU2476274308.USD","LU1961090484.USD","BK1515","02268","BK1161","IE00B5MMRT66.SGD","LU1969619763.USD","BK1574","LU0348767384.USD","BK1191","LU0348766576.USD","LU0348825331.USD","BK1141","159992","LU1720050803.USD","LU2328871848.SGD","LU2476274720.SGD","LU0348827113.USD","LU0561508036.HKD","IE00BPRC5H50.USD","01672","LU0348784397.USD","LU0417516738.SGD","LU0634319403.HKD","00460","LU0417516571.SGD","LU2399975544.HKD","LU0348783233.USD","159938","02162"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636483820","title":"【券商聚焦】中信建投：创新药迎盈利兑现期 国内商业化与海外授权双轮驱动业绩增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2636483820","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636483820?lang=zh_cn&edition=full","pubTime":"2026-05-18 09:32","pubTimestamp":1779067963,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，2026年上半年医药行业触底回暖，创新药迎来盈利兑现期，国内商业化与海外授权双轮驱动业绩增长，多家企业扭亏。26Q1对外授权总额超600亿美元，ADC、双抗等前沿赛道交易持续火热。2026年ASCO年会94项中国研究中选口头报告，依沃西单抗登上全体大会，标志着中国创新药全球学术影响力迈上新台阶。国内支付端医保谈判与商保目录合力支持真创新。建议关注创新药国际化、边际改善等结构性机会。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/NjdhYmE3ZDczMTc4NjgyMDYzMDA3NjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1981512","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","01877","01093","SG9999002562.SGD","LU1242518857.USD","LU1152091168.USD","LU1688375341.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU0417516738.SGD","06185","09688","06978","BK1588","LU0588546209.SGD","BK1574","LU1969619763.USD","LU0979878070.USD","LU0516422952.EUR","LU0456827905.SGD","LU2097828631.EUR","LU0348827113.USD","LU0561508036.HKD","601066","IE00BZ08YS42.EUR","IE00B0JY6N72.USD","02269","09926","LU0516423174.USD","LU1303224171.USD","LU2097828557.USD","02616","LU0039217434.USD","01177","09995","LU1152091754.HKD","02142","IE00BZ08YR35.GBP","BK1161","BK1141","LU0359202008.SGD","159992","LU2399975544.HKD","LU1226287875.USD","LU0326950275.SGD","IE00BZ08YT58.USD","LU1242518931.SGD","LU2097828474.EUR","01801","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636043954","title":"2026年医保商保“双目录”调整方案“划重点”","url":"https://stock-news.laohu8.com/highlight/detail?id=2636043954","media":"新京报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636043954?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:49","pubTimestamp":1779065340,"startTime":"0","endTime":"0","summary":"根据调整方案，2020年1月1日后国家药监部门附条件批准上市、且于2023年1月1日起至此次方案公布之日期间转为常规批准的新通用名药品，可以申报今年医保目录。同步启动的2026年商业健康保险创新药品目录调整，主要纳入超出“保基本”定位、暂时无法纳入医保目录但创新程度高、临床价值大、患者获益显著且适保性强的创新药，申报流程与医保目录基本相同。","market":"hk","thumbnail":"https://media.bjnews.com.cn/cover/2024/12/23/5535172268222656082.jpeg?x-oss-process=image/resize,m_lfit,w_365","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/cover/2024/12/23/5535172268222656082.jpeg?x-oss-process=image/resize,m_lfit,w_365"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1779065057129206.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1779065057129206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["IPOS","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636017909","title":"券商晨会精华 | 关注创新药国际化、边际改善等结构性机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2636017909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636017909?lang=zh_cn&edition=full","pubTime":"2026-05-18 08:31","pubTimestamp":1779064269,"startTime":"0","endTime":"0","summary":"在今日券商晨会上，中信建投认为，关注创新药国际化、边际改善等结构性机会。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518083143_48238.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518083143_48238.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/content/detail/1442690.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhitongcaijing_hushen_highlight","symbols":["BK1574","06978","159992","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636092964","title":"资金悄然“换道”？港股通创新药跌出性价比，520880迅猛吸金超5亿！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636092964","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636092964?lang=zh_cn&edition=full","pubTime":"2026-05-17 19:46","pubTimestamp":1779018360,"startTime":"0","endTime":"0","summary":"5月15日，大市深度调整，港股通创新药继续下行，康方生物、信达生物、百济神州、石药集团、中国生物制药等权重龙头普跌。100%创新药研发标的——港股通创新药ETF华宝放量收跌2.14%四连阴，场内价格直逼历史低点。　　本周，港股通创新药ETF华宝累跌6.91%，周线收出四连阴。截至5月14日，港股通创新药ETF华宝近10日累计获超5.35亿元净申购，基金份额亦水涨船高，升至53.42亿份新高！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-05-17/doc-inhyfhfe4569000.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["VXUS","BK1574","BK4588","520880","BK4585","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635704654","title":"全球首创新药“硬实力”领跑，丹诺医药-B(06872)开启招股掘金抗感染赛道","url":"https://stock-news.laohu8.com/highlight/detail?id=2635704654","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635704654?lang=zh_cn&edition=full","pubTime":"2026-05-15 16:30","pubTimestamp":1778833820,"startTime":"0","endTime":"0","summary":"5月6日，丹诺医药(苏州)股份有限公司顺利通过港交所主板上市聆讯，并已于5月14日正式开启招股，中信证券、农银国际担任联席保荐人。弗若斯特沙利文数据显示，幽门螺杆菌感染作为全球范围内的高发疾病，2024年全球治疗市场规模69亿美元，预计至2035年将攀升至161亿美元。在幽门螺杆菌感染治疗领域之外，丹诺医药在植入体相关细菌生物膜感染治疗方面同样取得了重要突破。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442187.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159992","06978","BK1574","IPOS","BK1161","06872"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706477","title":"《药品试验数据保护实施办法》发布 国家药监局：予创新药试验数据6年保护期","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706477","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635706477?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:20","pubTimestamp":1778829648,"startTime":"0","endTime":"0","summary":"第十一条对符合数据保护条件的药品，国家药监局在药品批准证明文件中标注该药品的数据保护信息。数据保护终止的，国家药监局发布终止数据保护公告，药审中心根据公告，更新数据保护专栏中的相关信息。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442160.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","159992","BK1161","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635737027","title":"创新药概念局部异动","url":"https://stock-news.laohu8.com/highlight/detail?id=2635737027","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635737027?lang=zh_cn&edition=full","pubTime":"2026-05-15 09:50","pubTimestamp":1778809834,"startTime":"0","endTime":"0","summary":"创新药概念局部异动","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605153738502053.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605153738502053.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1161","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635336766","title":"港股通创新药三连跌，520880持续溢价交易，此前10日吸金超4.34亿元！出海与政策双线驱动，机构提示配置机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2635336766","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635336766?lang=zh_cn&edition=full","pubTime":"2026-05-14 10:45","pubTimestamp":1778726700,"startTime":"0","endTime":"0","summary":"5月14日早盘，港股通创新药冲高回落，权重龙头集体飘绿，康方生物、三生制药跌逾3%，百济神州、石药集团、翰森制药跌逾1%。100%创新药研发标的——港股通创新药ETF华宝现跌1.46%，振幅超2.7%，连续3日下跌。　　值得关注的是，520880场内延续宽幅溢价，显示买盘资金仍活跃。近期板块震荡下行区间，资金频频增仓，截至5月13日，520880近10日累计吸金超4.3亿元。　　产业方面，日前恒瑞医药与BMS达成152亿美元全球合作，首付款6亿美元。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-05-14/doc-inhxvpqn0184733.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK4585","520880","BK4588","159992","VXUS","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635768379","title":"中国生物制药附属减肥创新药亮相欧洲大会：体外活性提升10倍以上，联合用药脂肪减少量提高1.5-2倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2635768379","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635768379?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:53","pubTimestamp":1778719980,"startTime":"0","endTime":"0","summary":"5月14日，中国生物制药（01177）发布公告，本公司附属公司正大天晴药业集团股份有限公司自主开发的创新药TQF6422“ActRIIA/B单抗”临床前研究数据已于2026年欧洲肥胖大会（ECO）公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143736704546.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["01177","06978","HK0000165453.HKD","BK1161","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","BK1521","BK1515","BK1574","IE00BZ08YT58.USD","BK1191","BK1589","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750130","title":"润都股份：公司近期获批的盐酸去甲乌药碱注射液为全球首创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750130","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635750130?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:51","pubTimestamp":1778719868,"startTime":"0","endTime":"0","summary":"证券之星消息，润都股份05月13日在投资者关系平台上答复投资者关心的问题。关于您提出的问题，现回复如下： 1、公司近期获批的盐酸去甲乌药碱注射液为全球首创新药。随着公司对该创新药优势的学术推广和国家对精准诊疗理念的普及，盐酸去甲乌药碱注射液有望惠及更多患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK1574","BK0239","BK1161","002923","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635750938","title":"众生药业：ZSP1601片是治疗MASH首创一类创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2635750938","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635750938?lang=zh_cn&edition=full","pubTime":"2026-05-14 08:48","pubTimestamp":1778719692,"startTime":"0","endTime":"0","summary":"证券之星消息，众生药业05月13日在投资者关系平台上答复投资者关心的问题。请问公司1601非酒精型脂肪肝创新药对酒精性脂肪肝是否具有治疗效果？公司ZSP1601片是具有全球自主知识产权、全新作用机制的治疗代谢功能障碍相关脂肪性肝炎首创一类创新药，为国家重大新药创制项目。公司始终以满足未被满足的临床需求为导向，未来，公司将根据实际情况，综合考虑ZSP1601片的适应症拓展，相关信息请以公司公告为准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400008417.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK0188","002317","06978","BK1574","BK0077","BK0239","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635278144","title":"创新药板块震荡下挫，港股通创新药ETF易方达（159316）逆势获5000万份净申购","url":"https://stock-news.laohu8.com/highlight/detail?id=2635278144","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635278144?lang=zh_cn&edition=full","pubTime":"2026-05-13 19:50","pubTimestamp":1778673024,"startTime":"0","endTime":"0","summary":"5月13日，创新药赛道震荡下挫，截至收盘，恒生港股通创新药指数下跌1.9%，中证创新药产业指数下跌1.3%，资金逆势布局，港股通创新药ETF易方达全天净申购达5000万份。兴业证券表示，中国创新药具备高效率、低成本的开发优势，在热门技术赛道如 ADC、双抗、小核酸等具备竞争优势，有望持续展现行业竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/SS2026051300039856.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","06978","BK1574","159992","159316"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635850209","title":"今日昂利康（002940）涨停分析：集采中选、创新药与宠物药驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2635850209","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635850209?lang=zh_cn&edition=full","pubTime":"2026-05-13 15:46","pubTimestamp":1778658379,"startTime":"0","endTime":"0","summary":"证券之星消息，昂利康5月13日涨停收盘，收盘价36.43元。今日昂利康涨停的可能因素有：1、12个产品拟中选国家集采接续采购，对应2024年营收占比13.93%，中标可获2–3年稳定销售周期；2、创新药ALK-N001研发持续推进并进入临床阶段，11.2亿元定增资金全部投入创新药研发；3、宠物药布局加速落地，获批‘吸入用七氟烷（宠物用）’等批件，覆盖超4000家宠物医院；4、2025年业绩预增显著，归母净利润预计增长36.93%–71.78%，扣非净利润增长46.68%–104.52%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300023985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["06978","BK0239","BK1161","159992","002940","BK1574"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.eaal.net","stockEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":-0.7552},{"period":"3month","weight":-0.6732},{"period":"6month","weight":-0.7331},{"period":"1year","weight":-0.7629},{"period":"ytd","weight":-0.7167}],"compareEarnings":[{"period":"1week","weight":-0.0277},{"period":"1month","weight":-0.0185},{"period":"3month","weight":-0.0386},{"period":"6month","weight":-0.006},{"period":"1year","weight":0.0998},{"period":"ytd","weight":0.0017}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化的投资控股公司。该公司的非转基因细胞产品管线包括扩增活化淋巴细胞（EAL）和6B11-OCIK注射液。该公司的嵌合抗原受体T（CAR-T）细胞产品管线包括CAR-T-19注射液、迪诺仑赛注射液和aT19注射液。该公司的T细胞受体工程化T细胞疗法（TCR-T）细胞产品管线包括YT003、YT008及YT007。该公司主要在中国市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074078},{"month":2,"riseRate":0.666667,"avgChangeRate":0.181642},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.080929},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.167652},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.065612},{"month":6,"riseRate":0.8,"avgChangeRate":0.080731},{"month":7,"riseRate":0.2,"avgChangeRate":-0.000149},{"month":8,"riseRate":0.5,"avgChangeRate":0.012587},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.035807},{"month":10,"riseRate":0.5,"avgChangeRate":-0.057833},{"month":11,"riseRate":0.5,"avgChangeRate":0.001253},{"month":12,"riseRate":0.666667,"avgChangeRate":0.067669}],"exchange":"SEHK","name":"永泰生物-B","nameEN":"IMMUNOTECH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"永泰生物-B,06978,永泰生物-B股票,永泰生物-B股票老虎,永泰生物-B股票老虎国际,永泰生物-B行情,永泰生物-B股票行情,永泰生物-B股价,永泰生物-B股市,永泰生物-B股票价格,永泰生物-B股票交易,永泰生物-B股票购买,永泰生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"永泰生物-B(06978)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供永泰生物-B(06978)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}